Cell And Gene Therapy Overview: Unsurpassed Knowledge In Scale Up And Commercialization

Scaling advanced therapies from clinical development to commercial supply requires specialized facilities, reliable testing, and tight control across every manufacturing stage. Novartis Contract Manufacturing offers integrated capabilities for plasmid DNA, cell therapy, and gene therapy, including cell banking, viral vector production, onsite testing, and support for both dedicated and multiproduct programs. Its experience spans autologous therapies, fresh and frozen workflows, adherent and suspension processes up to 1,000 L, and plasmid DNA production from milligram quantities to 150 g. A global manufacturing network supports clinical and commercial supply, backed by more than 40 years of GMP experience and products delivered to over 50 countries.

Explore the available platforms, facilities, and services that can help advance complex therapies toward commercialization.